NEW YORK ( TheStreet) -- CHANGE IN RATINGS Alimera Sciences ( ALM) initiated at Citi with a Buy rating and $15 price target. Several upcoming catalysts for the company's lead product, lluvien. Alimera Sciences ( ALM) initiated at Credit Suisse with an Outperform rating and $16 price target. Alimera's healthcare products can achieve high margins and rapid profitability. Autozone ( AZO) rated new Hold at ThinkEquity. Valuation call, as earnings tailwinds could moderate in the coming quarters. CA ( CA) downgraded at Goldman from Neutral to Sell. $20 price target. Company is facing currency headwinds and is facing a year of strategic transition. Coach ( COH) rated new Buy at ThinkEquity. Management has positioned the company well, with lower price points. Cypress Semiconductor ( CY) rated new Buy at Sterne Agee. $14 price target. Touch handset sales should drive growth. Deere ( DE) upgraded at Morgan Joseph from Hold to Buy. Company seeing higher demand from domestic row farmers and in Brazil. Excel Trust ( EXL) initiated at Barclays with an Overweight rating and $15 price target. The shopping center REIT is well positioned to take advantage of significant buying opportunities over next several years. Great Atlantic & Pacific Tea ( GAP) initiated at Citi with a Hold rating and $6 price target. There could be significant upside if turnaround initiatives begin. Glaxo SmithKline ( GSK) upgraded at Jefferies from Hold to Buy. Company has a strong pipeline and should benefit from currency volatility. Impax Laboratories ( IPXL) downgraded at Wells to Market Perform. Estimates raised, but the stock is already pricing in near-term growth. Jabil Circuit ( JBL) upgraded at UBS from Neutral to Buy. $19 price target. Stock is down 30% over the past two months and appears attractively valued at less than 9 times earnings. Joy Global ( JOYG) upgraded at Goldman from Neutral to Buy. $61 price target. Estimates also raised, as higher mining production should continue to boost CapEx rates. J.P. Morgan ( JMP) upgraded at UBS from Neutral to Buy. $50 price target. Company has a solid footing and the potential to generate above-average earnings growth.